{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:17:06Z","timestamp":1782379026138,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1124\/dmd.124.001751","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T19:25:19Z","timestamp":1727119519000},"page":"1379-1387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites"],"prefix":"10.1016","volume":"52","author":[{"given":"Ulrike","family":"Glaenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-4394","authenticated-orcid":false,"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Eggimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Hackling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc Alexis","family":"Leuthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiya","family":"Bebrevska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.124.001751_bib1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/psp4.12466","article-title":"The Importance of the Human Mass Balance Study in Regulatory Submissions","volume":"8","author":"Coppola","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.124.001751_bib2","unstructured":"European Medicines Agency (2012a) Kalydeco summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kalydeco-epar-product-information_en.pdf. Accessed August 01, 2023."},{"key":"10.1124\/dmd.124.001751_bib3","unstructured":"European Medicines Agency (2012b) Guideline on the investigation of drug interactions CPMP\/EWP\/560\/95\/Rev. 1 Corr. 2. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed July 20, 2023."},{"key":"10.1124\/dmd.124.001751_bib4","unstructured":"European Medicines Agency (2012c) ICH guideline M3 (R2) - questions and answers. https:\/\/www.ema.europa.eu\/en\/documents\/other\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en.pdf. Accessed July 31, 2023."},{"key":"10.1124\/dmd.124.001751_bib5","unstructured":"European Medicines Agency (2013) Overview of comments received on \u2018Guideline on the Investigation of Drug Interactions\u2019 (EMA\/CHMP\/EWP\/125211\/2010). https:\/\/www.ema.europa.eu\/en\/documents\/other\/overview-comments-received-guideline-investigation-drug-interactions_en.pdf. Accessed July 20, 2023."},{"key":"10.1124\/dmd.124.001751_bib6","doi-asserted-by":"crossref","first-page":"7241","DOI":"10.1021\/acs.jmedchem.1c00343","article-title":"Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease","volume":"64","author":"Grand","year":"2021","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.124.001751_bib7","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/cells10112844","article-title":"CFTR Protein: Not Just a Chloride Channel?","volume":"10","author":"Hanssens","year":"2021","journal-title":"Cells"},{"key":"10.1124\/dmd.124.001751_bib8","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jcf.2020.11.002","article-title":"Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)","volume":"20","author":"Kazani","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1124\/dmd.124.001751_bib9","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1124\/dmd.122.001240","article-title":"Mass Balance and Absorption, Distribution, Metabolism, and Excretion Properties of Balcinrenone following Oral Administration in Combination with Intravenous Microtracer in Healthy Subjects","volume":"51","author":"Lindmark","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.124.001751_bib10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17425255.2017.1364362","article-title":"A decade of drug metabolite safety testing: industry and regulatory shared learning","volume":"13","author":"Luffer-Atlas","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.124.001751_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01307-2022","article-title":"Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond","volume":"61","author":"Mall","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1124\/dmd.124.001751_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1164\/rccm.202303-0458OC","article-title":"Icenticaftor, a CFTR Potentiator, in COPD: a Multicenter, Parallel-Group, Double-Blind Clinical Trial","volume":"208","author":"Martinez","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/dmd.124.001751_bib13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-2600(15)00201-5","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial","volume":"3","author":"Moss","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1124\/dmd.124.001751_bib14","unstructured":"Pharmacy180.com Biopharmaceutics and Pharmacokinetics: Nonlinear Pharmacokinetics. Causes of. https:\/\/www.pharmacy180.com\/article\/causes-of-nonlinearity-2529\/. Accessed August 13, 2024."},{"key":"10.1124\/dmd.124.001751_bib15","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/cts.13403","article-title":"Human radiolabeled mass balance studies supporting the FDA approval of new drugs","volume":"15","author":"Ramamoorthy","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.124.001751_bib16","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.124.001751_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1124\/dmd.124.001751_bib18","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/COPD.S257474","article-title":"Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial","volume":"15","author":"Rowe","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1124\/dmd.124.001751_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6567578","article-title":"Cigarette Smoke-Induced Acquired Dysfunction of Cystic Fibrosis Transmembrane Conductance Regulator in the Pathogenesis of Chronic Obstructive Pulmonary Disease","volume":"2018","author":"Shi","year":"2018","journal-title":"Oxid Med Cell Longev"},{"key":"10.1124\/dmd.124.001751_bib20","unstructured":"US Food and Drug Administration (2012) Kalydeco prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203188s022l_207925s003lbl.pdf. Accessed August 01, 2023."},{"key":"10.1124\/dmd.124.001751_bib21","unstructured":"US Food and Drug Administration (2020) Safety testing of drug metabolites: guidance for industry. https:\/\/www.fda.gov\/media\/72279\/download. Accessed August 08, 2023."},{"key":"10.1124\/dmd.124.001751_bib22","unstructured":"US Food and Drug Administration (2024) Clinical pharmacology considerations for human radiolabeled mass balance studies: Guidance for industry. https:\/\/www.fda.gov\/media\/158178\/download. Accessed August 16, 2024."},{"key":"10.1124\/dmd.124.001751_bib23","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/dmd.124.001751_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.trsl.2016.08.002","article-title":"Gut microbiome interactions with drug metabolism, efficacy, and toxicity","volume":"179","author":"Wilson","year":"2017","journal-title":"Transl Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624159417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624159417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.124.001751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T01:09:02Z","timestamp":1743642542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624159417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0090955624159417"],"URL":"https:\/\/doi.org\/10.1124\/dmd.124.001751","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absorption, Distribution, Metabolism, and Excretion of Icenticaftor (QBW251) in Healthy Male Volunteers at Steady State and In Vitro Phenotyping of Major Metabolites","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.124.001751","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}